Format

Send to

Choose Destination
Tumour Biol. 2016 Aug;37(8):11209-18. doi: 10.1007/s13277-016-4994-1. Epub 2016 Mar 4.

DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.

Author information

1
Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, China.
2
Department of Stereotactic Radiosurgery, Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, China.
3
Department of Dermatology, Affiliated Huai'an Hospital of Xuzhou Medical College, Huai'an, 223002, China.
4
Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, China. dr.guanjiang@gmail.com.

Abstract

Malignant melanoma is an aggressive, highly lethal dermatological malignancy. Chemoresistance and rapid metastasis limit the curative effect of multimodal therapies like surgery or chemotherapy. The suicide enzyme O6-methylguanine-DNA methyltransferase (MGMT) removes adducts from the O6-position of guanine to repair DNA damage. High MGMT expression is associated with resistance to therapy in melanoma. However, it is unknown if MGMT is regulated by DNA methylation or histone acetylation in melanoma. We examined the effects of the DNA methylation inhibitor 5-Aza-2'-deoxycytidine and histone deacetylase inhibitor Trichostatin A alone or in combination on MGMT expression and promoter methylation and histone acetylation in A375, MV3, and M14 melanoma cells. This study demonstrates that MGMT expression, CpG island methylation, and histone acetylation vary between melanoma cell lines. Combined treatment with 5-Aza-2'-deoxycytidine and Trichostatin A led to reexpression of MGMT, indicating that DNA methylation and histone deacetylation are associated with silencing of MGMT in melanoma. This study provides information on the role of epigenetic modifications in malignant melanoma that may enable the development of new strategies for treating malignant melanoma.

KEYWORDS:

Acetylation; MGMT; Melanoma; Methylation; Temozolomide

PMID:
26943799
DOI:
10.1007/s13277-016-4994-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center